Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers.
Maine CJ, Miyake-Stoner SJ, Spasova DS, Picarda G, Chou AC, Brand ED, Olesiuk MD, Domingo CC, Little HJ, Goodman TT, Posy JL, Gonzalez J, Bayone TL, Sparks J, Gary EN, Xiang Z, Tursi NJ, Hojecki CE, Ertl HCJ, Weiner DB, Casmil IC, Blakney AK, Essink B, Somodevilla G, Wang NS, Geall AJ, Goldberg Z, Aliahmad P.
Maine CJ, et al. Among authors: weiner db.
Nat Commun. 2025 Jan 7;16(1):456. doi: 10.1038/s41467-025-55843-9.
Nat Commun. 2025.
PMID: 39774967
Free PMC article.
Clinical Trial.